Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluoromannitol
- Development stage
- Unknown
- Lead developer
- St. Jude Children's Research Hospital
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Fluoromannitol (specifically [18F]fluoromannitol or [18F]FMtl) is a novel, pathogen-specific radiopharmaceutical PET tracer developed by St. Jude Children's Research Hospital. It is designed to noninvasively detect and differentiate active bacterial infections from viral infections and sterile inflammation. The tracer exploits the bacterial-specific mannitol transport and metabolism pathway (mediated by the mannitol-specific phosphotransferase system), which is minimal or absent in mammalian cells. This allows [18F]fluoromannitol to rapidly and selectively accumulate in both Gram-positive and Gram-negative bacteria at infection sites. It is being evaluated in clinical trials for safety, biodistribution, and its potential to diagnose deep-seated infections such as osteomyelitis and prosthetic joint infections, particularly in patients with sickle cell disease or cancer.
- Other names
- 18F-FMtl18F-fluoromannitol2-18F-fluoro-2-deoxy-mannitol2-deoxy-2-[18F]fluoro-D-mannitol2-deoxy-2-fluoro-D-mannitol2-fluoro-2-deoxy-D-mannitol[18F]FMtl[18F]fluoromannitol
02
Targets
EIIMtl (Bacterial mannitol-specific phosphotransferase system, Enzyme II complex)
Beyond the preview
Go deeper on fluoromannitol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluoromannitol.